{"id":1021256,"date":"2026-11-16T08:25:19","date_gmt":"2026-11-16T13:25:19","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/esmo-rare-cancers-publishes-case-report-detailing-eight-year-response-to-relacorilant-plus-nab-paclitaxel-in-metastatic-vulvar-cancer\/"},"modified":"2026-11-16T08:25:19","modified_gmt":"2026-11-16T13:25:19","slug":"esmo-rare-cancers-publishes-case-report-detailing-eight-year-response-to-relacorilant-plus-nab-paclitaxel-in-metastatic-vulvar-cancer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/esmo-rare-cancers-publishes-case-report-detailing-eight-year-response-to-relacorilant-plus-nab-paclitaxel-in-metastatic-vulvar-cancer\/","title":{"rendered":"ESMO Rare Cancers Publishes Case Report Detailing Eight-Year Response to Relacorilant Plus Nab-Paclitaxel in Metastatic Vulvar Cancer"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>ESMO Rare Cancers Publishes Case Report Detailing Eight-Year Response to Relacorilant Plus Nab-Paclitaxel in Metastatic Vulvar Cancer<\/b><\/p>\n<p>REDWOOD CITY, Calif.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nCorcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced publication of a peer-reviewed case report in <i>ESMO Rare Cancers<\/i>, regarding an approximately eight-year response to relacorilant plus nab-paclitaxel in a patient with metastatic vulvar cancer.<\/p>\n<p>\nThe publication, \u201cLong-term Response to Relacorilant Plus Nab-Paclitaxel in a Patient with Metastatic Vulvar Cancer\u201d (Tsang et al), can be accessed at: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.esmorarecancers.org%2Farticle%2FS3050-4619%252826%252900437-5%2Ffulltext&amp;esheet=54641054&amp;newsitemid=20261116644531&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.esmorarecancers.org%2Farticle%2FS3050-4619%2826%2900437-5%2Ffulltext&amp;index=1&amp;md5=0635b91926a11ce7dc2930e6e5b1e573\">https:\/\/www.esmorarecancers.org\/article\/S3050-4619(26)00437-5\/fulltext<\/a>.<\/p>\n<p>\n\u201cMetastatic vulvar cancer is an exceptionally challenging disease to treat, and its impact on patients is profound,\u201d said Pamela Munster, M.D., Professor of Medicine in Oncology, Associate Director for early phase clinical trials and Inaugural Associate Director for Early Detection and Interception Research at the Stanford Cancer Institute. \u201cSustained disease control continuing at eight years is a remarkable milestone in this setting and speaks to the benefit and tolerability of this regimen. This case reinforces the rationale for further research into targeting glucocorticoid receptor signaling in patients with various types of solid tumors.\u201d<\/p>\n<p>\n\u201cWe are grateful for the academic collaborators and partners who advance our science and deepen our understanding of glucocorticoid receptor antagonism\u2019s potential to help patients with serious diseases, including difficult-to-treat cancers like this one,\u201d said Joseph K. Belanoff, M.D., Corcept\u2019s Chief Executive Officer.<\/p>\n<p>\nThis case report describes a patient with heavily pretreated, recurrent, metastatic vulvar cancer who achieved a prolonged clinical benefit with relacorilant plus nab-paclitaxel. Her duration of response exceeded 105 months, more than 20 times longer than her prior taxane-based regimen. As of July 2026, the patient remains in good health on ongoing treatment with stable disease and no new lesions. Although notable, this is limited to one patient and should not be considered representative of the broader patient population with metastatic vulvar cancer.<\/p>\n<p>\nIn the United States, vulvar cancer accounts for about 0.3% of new cancers in women. While rare, vulvar cancer can cause significant morbidity and, particularly when advanced or recurrent, can be difficult to treat.<\/p>\n<p><i>ESMO Rare Cancers <\/i>is a peer-reviewed, open-access medical journal published by the European Society for Medical Oncology (ESMO). Relacorilant is not approved for the treatment of metastatic vulvar cancer.<\/p>\n<p><b>About Relacorilant<\/b><\/p>\n<p>\nRelacorilant is a selective, reversible glucocorticoid receptor antagonist. It is approved by the U.S. Food and Drug Administration under the trade name Lifyorli<sup>\u00ae<\/sup> for use in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab. Corcept is developing relacorilant in platinum-sensitive ovarian, endometrial, cervical, pancreatic and prostate cancers. Relacorilant is proprietary to Corcept and is protected by composition of matter, method of use, formulation, manufacturing and other patents.<\/p>\n<p><b>About Cortisol&#8217;s Role in Oncology<\/b><\/p>\n<p>\nCortisol plays a role in tumor growth through several mechanisms. It helps solid tumors resist chemotherapy by inhibiting cellular apoptosis \u2014 the tumor-killing effect chemotherapy is meant to stimulate. In some cancers, cortisol promotes tumor growth by activating oncogenic signaling in the cells to which it binds. Cortisol also suppresses the body&#8217;s immune response, which weakens its ability to fight all diseases, including cancer.<\/p>\n<p><b>About Corcept Therapeutics<\/b><\/p>\n<p>\nFor over 25 years, Corcept has focused on cortisol modulation and its potential to treat patients with a wide variety of serious disorders. We have discovered more than 1,000 proprietary selective glucocorticoid receptor antagonists. Our development activities include advanced clinical trials in patients with hypercortisolism, a variety of solid tumors, ALS and liver disease. In 2012, we introduced Korlym<sup>\u00ae<\/sup>, the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with endogenous Cushing\u2019s syndrome. In March 2026, we introduced Lifyorli<sup>\u00ae<\/sup> as a treatment for patients with platinum-resistant ovarian cancer. We are headquartered in Redwood City, California. For more information, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2FCorcept.com&amp;esheet=54641054&amp;newsitemid=20261116644531&amp;lan=en-US&amp;anchor=Corcept.com&amp;index=2&amp;md5=622e0298fddc98070d90aa712c501414\">Corcept.com<\/a>.<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p>\nStatements in this press release, other than statements of historical fact, are forward-looking statements based on our current plans and expectations and are subject to risks and uncertainties that might cause our actual results to differ materially from any future results expressed or implied by such forward-looking statements.<\/p>\n<p>\nIn this press release, forward-looking statements include statements concerning: the potential of relacorilant for the treatment of vulvar cancer; possibilities for further research into treatments targeting glucocorticoid receptor signaling in patients with various types of solid tumors; glucocorticoid receptor antagonism\u2019s potential to help patients with serious diseases, including difficult-to-treat cancers; and our further development of relacorilant in platinum-sensitive ovarian, endometrial, cervical, pancreatic and prostate cancers.<\/p>\n<p>\nA further description of risks and uncertainties can be found in our SEC filings, which are available at our website and the SEC\u2019s website. These risks and uncertainties include, but are not limited to, those related to: our ability to operate our business; our efforts to study and develop Korlym, relacorilant, miricorilant, dazucorilant, nenocorilant and our other product candidates; those molecules\u2019 clinical attributes; regulatory approvals, mandates, oversight and other requirements imposed on our products or our business by laws, regulations or discretion of government authorities; and the scope and protective power of our intellectual property. We disclaim any intention or duty to update forward-looking statements made in this press release.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261116644531r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20261116644531\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20261116644531\/en\/<\/a><\/span><\/p>\n<p>\nInvestor inquiries:<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:ir@corcept.com\">ir@corcept.com<\/a><\/p>\n<p>\nMedia inquiries:<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:communications@corcept.com\">communications@corcept.com<br \/>\n<\/a><br \/><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.corcept.com%2F&amp;esheet=54641054&amp;newsitemid=20261116644531&amp;lan=en-US&amp;anchor=www.corcept.com&amp;index=3&amp;md5=eb5708887f225fcbd2c9de34c65e0910\">www.corcept.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> California United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Science Neurology Biotechnology Research Pharmaceutical Oncology Health Clinical Trials<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20261116644531\/en\/2330117\/3\/Corcept_logo_new_black.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>ESMO Rare Cancers Publishes Case Report Detailing Eight-Year Response to Relacorilant Plus Nab-Paclitaxel in Metastatic Vulvar Cancer REDWOOD CITY, Calif.&#8211;(BUSINESS WIRE)&#8211; Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced publication of a peer-reviewed case report in ESMO Rare Cancers, regarding an approximately eight-year response to relacorilant plus nab-paclitaxel in a patient with metastatic vulvar cancer. The publication, \u201cLong-term Response to Relacorilant Plus Nab-Paclitaxel in a Patient with Metastatic Vulvar Cancer\u201d (Tsang et al), can be accessed at: https:\/\/www.esmorarecancers.org\/article\/S3050-4619(26)00437-5\/fulltext. \u201cMetastatic vulvar cancer is an exceptionally challenging disease to treat, and its impact on patients &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/esmo-rare-cancers-publishes-case-report-detailing-eight-year-response-to-relacorilant-plus-nab-paclitaxel-in-metastatic-vulvar-cancer\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;ESMO Rare Cancers Publishes Case Report Detailing Eight-Year Response to Relacorilant Plus Nab-Paclitaxel in Metastatic Vulvar Cancer&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1021256","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ESMO Rare Cancers Publishes Case Report Detailing Eight-Year Response to Relacorilant Plus Nab-Paclitaxel in Metastatic Vulvar Cancer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/esmo-rare-cancers-publishes-case-report-detailing-eight-year-response-to-relacorilant-plus-nab-paclitaxel-in-metastatic-vulvar-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ESMO Rare Cancers Publishes Case Report Detailing Eight-Year Response to Relacorilant Plus Nab-Paclitaxel in Metastatic Vulvar Cancer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ESMO Rare Cancers Publishes Case Report Detailing Eight-Year Response to Relacorilant Plus Nab-Paclitaxel in Metastatic Vulvar Cancer REDWOOD CITY, Calif.&#8211;(BUSINESS WIRE)&#8211; Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced publication of a peer-reviewed case report in ESMO Rare Cancers, regarding an approximately eight-year response to relacorilant plus nab-paclitaxel in a patient with metastatic vulvar cancer. The publication, \u201cLong-term Response to Relacorilant Plus Nab-Paclitaxel in a Patient with Metastatic Vulvar Cancer\u201d (Tsang et al), can be accessed at: https:\/\/www.esmorarecancers.org\/article\/S3050-4619(26)00437-5\/fulltext. \u201cMetastatic vulvar cancer is an exceptionally challenging disease to treat, and its impact on patients &hellip; Continue reading &quot;ESMO Rare Cancers Publishes Case Report Detailing Eight-Year Response to Relacorilant Plus Nab-Paclitaxel in Metastatic Vulvar Cancer&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/esmo-rare-cancers-publishes-case-report-detailing-eight-year-response-to-relacorilant-plus-nab-paclitaxel-in-metastatic-vulvar-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-16T13:25:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261116644531r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esmo-rare-cancers-publishes-case-report-detailing-eight-year-response-to-relacorilant-plus-nab-paclitaxel-in-metastatic-vulvar-cancer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esmo-rare-cancers-publishes-case-report-detailing-eight-year-response-to-relacorilant-plus-nab-paclitaxel-in-metastatic-vulvar-cancer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"ESMO Rare Cancers Publishes Case Report Detailing Eight-Year Response to Relacorilant Plus Nab-Paclitaxel in Metastatic Vulvar Cancer\",\"datePublished\":\"2026-11-16T13:25:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esmo-rare-cancers-publishes-case-report-detailing-eight-year-response-to-relacorilant-plus-nab-paclitaxel-in-metastatic-vulvar-cancer\\\/\"},\"wordCount\":962,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esmo-rare-cancers-publishes-case-report-detailing-eight-year-response-to-relacorilant-plus-nab-paclitaxel-in-metastatic-vulvar-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261116644531r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esmo-rare-cancers-publishes-case-report-detailing-eight-year-response-to-relacorilant-plus-nab-paclitaxel-in-metastatic-vulvar-cancer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esmo-rare-cancers-publishes-case-report-detailing-eight-year-response-to-relacorilant-plus-nab-paclitaxel-in-metastatic-vulvar-cancer\\\/\",\"name\":\"ESMO Rare Cancers Publishes Case Report Detailing Eight-Year Response to Relacorilant Plus Nab-Paclitaxel in Metastatic Vulvar Cancer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esmo-rare-cancers-publishes-case-report-detailing-eight-year-response-to-relacorilant-plus-nab-paclitaxel-in-metastatic-vulvar-cancer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esmo-rare-cancers-publishes-case-report-detailing-eight-year-response-to-relacorilant-plus-nab-paclitaxel-in-metastatic-vulvar-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261116644531r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-11-16T13:25:19+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esmo-rare-cancers-publishes-case-report-detailing-eight-year-response-to-relacorilant-plus-nab-paclitaxel-in-metastatic-vulvar-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esmo-rare-cancers-publishes-case-report-detailing-eight-year-response-to-relacorilant-plus-nab-paclitaxel-in-metastatic-vulvar-cancer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esmo-rare-cancers-publishes-case-report-detailing-eight-year-response-to-relacorilant-plus-nab-paclitaxel-in-metastatic-vulvar-cancer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261116644531r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261116644531r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esmo-rare-cancers-publishes-case-report-detailing-eight-year-response-to-relacorilant-plus-nab-paclitaxel-in-metastatic-vulvar-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ESMO Rare Cancers Publishes Case Report Detailing Eight-Year Response to Relacorilant Plus Nab-Paclitaxel in Metastatic Vulvar Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ESMO Rare Cancers Publishes Case Report Detailing Eight-Year Response to Relacorilant Plus Nab-Paclitaxel in Metastatic Vulvar Cancer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/esmo-rare-cancers-publishes-case-report-detailing-eight-year-response-to-relacorilant-plus-nab-paclitaxel-in-metastatic-vulvar-cancer\/","og_locale":"en_US","og_type":"article","og_title":"ESMO Rare Cancers Publishes Case Report Detailing Eight-Year Response to Relacorilant Plus Nab-Paclitaxel in Metastatic Vulvar Cancer - Market Newsdesk","og_description":"ESMO Rare Cancers Publishes Case Report Detailing Eight-Year Response to Relacorilant Plus Nab-Paclitaxel in Metastatic Vulvar Cancer REDWOOD CITY, Calif.&#8211;(BUSINESS WIRE)&#8211; Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced publication of a peer-reviewed case report in ESMO Rare Cancers, regarding an approximately eight-year response to relacorilant plus nab-paclitaxel in a patient with metastatic vulvar cancer. The publication, \u201cLong-term Response to Relacorilant Plus Nab-Paclitaxel in a Patient with Metastatic Vulvar Cancer\u201d (Tsang et al), can be accessed at: https:\/\/www.esmorarecancers.org\/article\/S3050-4619(26)00437-5\/fulltext. \u201cMetastatic vulvar cancer is an exceptionally challenging disease to treat, and its impact on patients &hellip; Continue reading \"ESMO Rare Cancers Publishes Case Report Detailing Eight-Year Response to Relacorilant Plus Nab-Paclitaxel in Metastatic Vulvar Cancer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/esmo-rare-cancers-publishes-case-report-detailing-eight-year-response-to-relacorilant-plus-nab-paclitaxel-in-metastatic-vulvar-cancer\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-16T13:25:19+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261116644531r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esmo-rare-cancers-publishes-case-report-detailing-eight-year-response-to-relacorilant-plus-nab-paclitaxel-in-metastatic-vulvar-cancer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esmo-rare-cancers-publishes-case-report-detailing-eight-year-response-to-relacorilant-plus-nab-paclitaxel-in-metastatic-vulvar-cancer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"ESMO Rare Cancers Publishes Case Report Detailing Eight-Year Response to Relacorilant Plus Nab-Paclitaxel in Metastatic Vulvar Cancer","datePublished":"2026-11-16T13:25:19+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esmo-rare-cancers-publishes-case-report-detailing-eight-year-response-to-relacorilant-plus-nab-paclitaxel-in-metastatic-vulvar-cancer\/"},"wordCount":962,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esmo-rare-cancers-publishes-case-report-detailing-eight-year-response-to-relacorilant-plus-nab-paclitaxel-in-metastatic-vulvar-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261116644531r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esmo-rare-cancers-publishes-case-report-detailing-eight-year-response-to-relacorilant-plus-nab-paclitaxel-in-metastatic-vulvar-cancer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/esmo-rare-cancers-publishes-case-report-detailing-eight-year-response-to-relacorilant-plus-nab-paclitaxel-in-metastatic-vulvar-cancer\/","name":"ESMO Rare Cancers Publishes Case Report Detailing Eight-Year Response to Relacorilant Plus Nab-Paclitaxel in Metastatic Vulvar Cancer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esmo-rare-cancers-publishes-case-report-detailing-eight-year-response-to-relacorilant-plus-nab-paclitaxel-in-metastatic-vulvar-cancer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esmo-rare-cancers-publishes-case-report-detailing-eight-year-response-to-relacorilant-plus-nab-paclitaxel-in-metastatic-vulvar-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261116644531r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-11-16T13:25:19+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esmo-rare-cancers-publishes-case-report-detailing-eight-year-response-to-relacorilant-plus-nab-paclitaxel-in-metastatic-vulvar-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/esmo-rare-cancers-publishes-case-report-detailing-eight-year-response-to-relacorilant-plus-nab-paclitaxel-in-metastatic-vulvar-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esmo-rare-cancers-publishes-case-report-detailing-eight-year-response-to-relacorilant-plus-nab-paclitaxel-in-metastatic-vulvar-cancer\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261116644531r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261116644531r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esmo-rare-cancers-publishes-case-report-detailing-eight-year-response-to-relacorilant-plus-nab-paclitaxel-in-metastatic-vulvar-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"ESMO Rare Cancers Publishes Case Report Detailing Eight-Year Response to Relacorilant Plus Nab-Paclitaxel in Metastatic Vulvar Cancer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1021256","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1021256"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1021256\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1021256"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1021256"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1021256"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}